Femasys Inc. FEMY
1.42 USD 0.00 (+0.18%)
Nov 10, 2026, 3:03 PM EST
1.35 Day range 1.51
1.26 52-week range 22.20
- YTD
- -87.65%
- 1 year
- -93.16%
News
benzinga.com Femasys Doubles Number Of Enrolling Facilities To 12 In Its FemBloc FINALE Pivotal Study Across U.S. Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI)…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. Tempest Therapeutics (NASDAQ:TPST) stock moved…
benzinga.com Femasys Files Prospectus Related To The Offer And Resale From Time To Time By The Selling Stockholders Of Up To An Aggregate Of 28,124,997 Shares Of Common Stock https://www.sec.gov/Archives/edgar/data/1339005/000114036126035625/ny20081537x1_s3.htm
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) shares moved…
benzinga.com Femasys Partners With UNC Health To Introduce Fertility Diagnostics, FemVue And SpermVue, Together With Femaseed Complete Within UNC Health OB/GYN Practice Locations -- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option --ATLANTA, Aug. 26, 2026 (GLOBE…
benzinga.com Femasys Secures FDA Pathway for Non-Surgical Contraceptive FDA clears modular PMA pathway for Femasys' FemBloc, an investigational non-surgical permanent birth control device for women in the US.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers ZeroStack (NASDAQ:ZSTK) stock increased by 440.2% to $9.94 during Wednesday's regular session. The company's market cap stands at $4.4 million. Tenon Medical (NASDAQ:TNON) shares moved…
- benzinga.com Femasys Q2 EPS $(1.08) Beats $(1.33) Estimate, Sales $756.716K Beat $730.667K Estimate Femasys (NASDAQ:FEMY) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(1.33) by 18.8 percent. This is a 66.25 percent increase over losses of $(3.20) per…
- benzinga.com Maxim Group Maintains Buy on Femasys, Lowers Price Target to $10 Maxim Group analyst Jason McCarthy maintains Femasys (NASDAQ:FEMY) with a Buy and lowers the price target from $30 to $10.
benzinga.com Femasys Announces $30M Private Placement Led By New Investors And Members Of Management Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's regular session. The company's market cap stands at $36.8 million. Wellgistics Health (NASDAQ:WGRX) shares…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Femasys Announces CE Mark Approval For FemHSG Catheter, Further Expanding Its Portfolio In Europe Through Commercial Partners Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today…- benzinga.com Femasys Announces First Revenue-Generating Commercial Use Of Its Fertility Portfolio In An OBGYN Setting, Led By FemaSeed As A First-Line Infertility Treatment The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shift of fertility care to women's primary physician, where earlier intervention can improve access and
- benzinga.com Femasys Collaborates With AMI Technologies To Roll Out, Commercialize Fertility Portfolio In Israel Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced…
benzinga.com Femasys Appoints John Canning COO Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced…- benzinga.com Femasys Q4 EPS $(0.06) Beats $(0.12) Estimate, Sales $813.387K Miss $1.450M Estimate Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.12) by 47.83 percent. This is a 73.91 percent increase over losses of $(0.23) per…
- benzinga.com Femasys Initiates Participant Enrollment In FINALE Pivotal Clinical Study Of FemBloc Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced…
- benzinga.com Lake Street Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $1.5 Lake Street analyst Benjamin Haynor initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating and announces Price Target of $1.5.
benzinga.com Femasys' FemBloc Permanent Birth Control System Gets Certification Under Medical Device Single Audit Program -- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance --ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY),…
benzinga.com Femasys Secures American Medical Association CPT Editorial Panel Approval For Category III CPT Code Covering Use Of FemaSeed For Intratubal Insemination -- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment --ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical…- benzinga.com Femasys Partners With OR Consulting Over Commercial Rollout Of Product Portfolio In Switzerland Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Femasys Gets Nasdaq's 180-Day Extension Through July 13 To Regain Compliance Femasys Inc. (NASDAQ: FEMY) ("Femasys" or the "Company"), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women…- benzinga.com Femasys Partners With Refuah Health Center To Offer FemaSeed As First Step In Infertility Treatment Process Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why Multi Ways Holdings Shares Are Trading Higher By Around 60%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Femasys Receives 510(k) Clearance From FDA For FemVue Controlled Device, Diagnostic Solution For Controlled Contrast Delivery To Evaluate Fallopian Tube Status -- Innovative single-device solution integrates proven FemVue and FemChec® technologies to support fallopian tube evaluation and improve workflow efficiency--ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE)…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com PharmaCyte Biotech Monetizes Femasys Stake; Cash And Securities Expected At ~$20M After Monetization, Up From $13.3M PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), further validating the Company's…
- benzinga.com Laidlaw & Co. Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $6.5 Laidlaw & Co. analyst Yale Jen initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating and announces Price Target of $6.5.
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Femasys Q3 EPS $(0.10) Beats $(0.12) Estimate, Sales $729.394K Miss $1.450M Estimate Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 13.04 percent. This is a 58.33 percent increase over losses of $(0.24) per…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com Femasys Announces Start Of Post-Market Surveillance Clinical Study For Its CE-Marked FemBloc Permanent Birth Control, Conducted Under EU Medical Device Regulation In Collaboration With Regional Medical Experts Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the commencement…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 'White House Set To Announce Proposal Seeking To Make I.V.F. More Accessible' - NY Times https://www.nytimes.com/2025/10/16/us/politics/trump-ivf-fertility.html
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Femasys Partners With Kebomed To Commercialize FemBloc Permanent Birth Control In France And Benelux Region Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announ